Patent protection for the first biopharmaceuticals is expiring in the next few years. The manufacture of so-called biosimilars or biogenerica is thus increasingly gaining in importance. A considerable proportion of the production costs of a pharmaceutical protein is the result of high purification costs. Advances in the field of analytical characterization of products have challenged the dogma that "the process determines the product". These advances open new paths to the manufacture of safe and, due to alternative cleaning processes, inexpensive biopharmaceuticals which then become globally available to more patients.